When it comes to disclosing clinical trial data, some drug makers are still keeping secrets, according to new research published in the journal BMJ Open.
According to the study, 35 percent of all trial results for 15 drugs that were approved by the Food and Drug Administration in 2012 were not disclosed. Additionally, nearly 30 percent of the trials conducted for those drugs failed to meet legal disclosure requirements.
“This confirms that pharmaceutical companies often fall below legal and ethical standards,” said Jennifer Miller, an assistant professor in the division of medical ethics at the New York University School of Medicine and a co-author of the study, which looked at 318 clinical trials involving almost 100,000 participants.
About the Author Reprints
